RNA Sequence Design
-
Optimization of CDS regions using artificial intelligence algorithms
-
Proprietary UTR screening technology for customized UTR design of RNA sequences
-
Integration of RNA secondary structure prediction tools to enhance RNA structural stability and translation efficiency
i-Core LNP? Precision Delivery Solutions
i-Core LNP? Pulmonary Nebulization Delivery System
-
High Stability Formulation: Unique formulation ensures lipid nanoparticles maintain stability under high-frequency impacts during nebulization. LNP particle characteristics remain consistent before and after nebulization, providing a reliable drug delivery platform.
-
Efficient Pulmonary Delivery: Advanced delivery system precisely and efficiently delivers mRNA/siRNA to target lung cells, ensuring therapeutic molecules reach their sites of action.
-
Precise Lung Targeting: Achieves specific organ targeting to the lungs, with loaded RNA expression primarily concentrated in lung tissue, significantly reducing off-target expression in liver/spleen and other non-target organs.
-
Applicability: Through local nebulization administration, this LNP delivery system demonstrates excellent tolerability in mouse/rat animal models, establishing a solid foundation for clinical applications.
i-Core LNP? Skin Delivery System
-
Superior Skin Targeting Performance: Unique LNP formulation specially designed for local skin treatment. After intradermal administration, mRNA expression is highly concentrated in target skin tissues, effectively avoiding off-target expression in non-target organs such as the liver, achieving precise treatment.
-
Significant Anti-Aging Effects: In UVB-induced skin aging models, low-dose COL3A1 mRNA-LNP administered intradermally effectively promotes collagen synthesis and replacement, significantly reducing wrinkle formation, providing an innovative solution for skin anti-aging.
-
Excellent Biosafety Profile: Minimal local injection irritation, significantly lower immunogenicity than existing LNP products on the market. Long-term safety studies have not identified spleen or liver toxicity, providing reliable safety assurance for clinical applications.
-
Applicability: Through local administration, this LNP delivery system demonstrates excellent tolerability in mouse/rat animal models, establishing a solid foundation for clinical applications.
i-Core LNP? Vaccine Delivery System
-
Proprietary IP Formulation System: Self-developed innovative ionizable lipid materials combined with precisely optimized formulation combinations, creating an advanced delivery platform with completely independent intellectual property rights.
-
Efficient Immune Organ Targeting: Following intramuscular (IM) administration, mRNA achieves efficient expression in key immune organs (lymph nodes, spleen). Its tissue distribution characteristics are consistent with internationally marketed products, ensuring maximized vaccine immune response.
-
Superior Protein Expression Kinetics: The expression kinetics of mRNA-encoded proteins after single administration are fully comparable to internationally marketed products, demonstrating stable and reliable therapeutic effects and lasting immune protection.
SuperLNP? Pre-formulated Lipid Nanoparticles
-
SuperLNP? offers a new model for efficient RNA encapsulation, providing GMP-grade standard pre-formulated LNPs for on-site preparation of RNA-LNP complexes. Compared to traditional methods, SuperLNP? eliminates the need for complex equipment. It only requires direct mixing with RNA solution before use to achieve efficient encapsulation, greatly shortening RNA-LNP preparation cycles and production costs.
-
SuperLNP? provides a new LNP platform for clinical research and commercial production with higher efficiency and lower costs.
